Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568843 | 0.87 | CNR1 (0.45) | SMN1; SMN2NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL19291677 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL2205503 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL25819222 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL25819677 | 0.83 | CHRM2 (0.48) | CHRM2CHRM1CHRM3ACACB | |
| SCHEMBL25819673 | 0.82 | CHRM2 (0.47) | CHRM2CHRM1CHRM3ACACB | |
| SCHEMBL2204692 | 0.82 | CHRM2 (0.47) | CHRM2CHRM1CHRM3ACACB | |
| SCHEMBL19291800 | 0.82 | CHRM2 (0.47) | CHRM2CHRM1CHRM3ACACB | |
| SCHEMBL25819791 | 0.79 | CHRM2 (0.46) | CHRM2CHRM1CHRM3ACACB | |
| SCHEMBL25825926 | 0.77 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9AALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | SMN1; SMN2 39/4885NPC1 47/4885RAB9A 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.